NewAmsterdam Pharma (NAMS) Current Assets (2021 - 2026)

NewAmsterdam Pharma has reported Current Assets for 6 years, with the latest figure at $658.0 million in Q1 2026.

• Quarterly Current Assets fell 19.49% year-over-year to $658.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $658.0 million (down 19.49% YoY) and the FY2025 annual result came in at $675.7 million, down 21.74% from the prior year.
• Current Assets declined to $658.0 million in Q1 2026 per NAMS's latest filing, from $675.7 million in the prior quarter.
• Over five years, Current Assets peaked at $863.4 million in Q4 2024 and troughed at $423879.1 in Q2 2023.
• A 5-year average of $557.7 million and a median of $572.9 million in 2024 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets declined 24.15% in 2023, then soared 104965.82% in 2024.
• Over 5 years, Current Assets stood at $457.2 million in 2022, then decreased by 24.15% to $346.8 million in 2023, then jumped by 148.97% to $863.4 million in 2024, then slipped by 21.74% to $675.7 million in 2025, then slipped by 2.61% to $658.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $658.0 million, $675.7 million, and $732.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.